These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 12150700)

  • 1. Current status and future development of antitubercular chemotherapy.
    Kremer LS; Besra GS
    Expert Opin Investig Drugs; 2002 Aug; 11(8):1033-49. PubMed ID: 12150700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An approach for the rational design of new antituberculosis agents.
    Pasqualoto KF; Ferreira EI
    Curr Drug Targets; 2001 Dec; 2(4):427-37. PubMed ID: 11732641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
    Tomioka H
    Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prospects for development of new antituberculous drugs].
    Tomioka H
    Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New treatment options for multidrug-resistant tuberculosis.
    Field SK; Fisher D; Jarand JM; Cowie RL
    Ther Adv Respir Dis; 2012 Oct; 6(5):255-68. PubMed ID: 22763676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multidrug-resistant Mycobacterium tuberculosis: molecular perspectives.
    Rattan A; Kalia A; Ahmad N
    Emerg Infect Dis; 1998; 4(2):195-209. PubMed ID: 9621190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in the diagnosis and treatment of multidrug-resistant tuberculosis.
    Ahmad S; Mokaddas E
    Respir Med; 2009 Dec; 103(12):1777-90. PubMed ID: 19660927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. QSAR based design of new antitubercular compounds: improved isoniazid derivatives against multidrug-resistant TB.
    Martins F; Ventura C; Santos S; Viveiros M
    Curr Pharm Des; 2014; 20(27):4427-54. PubMed ID: 24245762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The resumption of consumption -- a review on tuberculosis.
    Ducati RG; Ruffino-Netto A; Basso LA; Santos DS
    Mem Inst Oswaldo Cruz; 2006 Nov; 101(7):697-714. PubMed ID: 17160276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DFT based QSAR/QSPR models in the development of novel anti-tuberculosis drugs targeting Mycobacterium tuberculosis.
    Rajkhowa S; Deka RC
    Curr Pharm Des; 2014; 20(27):4455-73. PubMed ID: 24245759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular genetics of drug resistance in Mycobacterium tuberculosis.
    Zhang Y; Young D
    J Antimicrob Chemother; 1994 Sep; 34(3):313-9. PubMed ID: 7829406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and bioactivity of antitubercular peptides and peptidomimetics: an update.
    De Leon Rodriguez LM; Kaur H; Brimble MA
    Org Biomol Chem; 2016 Jan; 14(4):1177-87. PubMed ID: 26645944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bedaquiline: a new hope to treat multi-drug resistant tuberculosis.
    Patel RV; Riyaz SD; Park SW
    Curr Top Med Chem; 2014; 14(16):1866-74. PubMed ID: 25262806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of resistance to anti-tuberculosis drugs in the clinical isolates of Mycobacterium tuberculosis from Slovakia through comparison between phenotypic and genetic methods and evaluation of resistance levels with clinical parameter.
    Mokry J; Porvaznik I; Kusnir P; Dohal M; Solovic I
    J Physiol Pharmacol; 2019 Feb; 70(1):. PubMed ID: 31172969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New tuberculostatic agents targeting nucleic acid biosynthesis: drug design using QSAR approaches.
    Bueno RV; Braga RC; Segretti ND; Ferreira EI; Trossini GH; Andrade CH
    Curr Pharm Des; 2014; 20(27):4474-85. PubMed ID: 24245758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TB drug discovery: addressing issues of persistence and resistance.
    Smith CV; Sharma V; Sacchettini JC
    Tuberculosis (Edinb); 2004; 84(1-2):45-55. PubMed ID: 14670345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Recent progress in mycobacteriology].
    Okada M; Kobayashi K
    Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of glucosyl-3-phosphoglycerate phosphatase as a novel drug target against resistant strain of Mycobacterium tuberculosis (XDR1219) by using comparative metabolic pathway approach.
    Uddin R; Zahra NU; Azam SS
    Comput Biol Chem; 2019 Apr; 79():91-102. PubMed ID: 30743161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.